Eli Lilly strengthens GI focus through $3.2B acquisition

Pharmaceutical company Eli Lilly plans to acquire Morphic, a biopharmaceutical company that specializes in treating gastroenterology patients, for $3.2 billion. 

Morphic's lead program is an oral treatment for inflammatory bowel disease patients, according to a July 8 news release. 

The molecule is also being evaluated to treat patients with ulcerative colitis and Crohn's disease. 

The transaction has been approved by the boards of directors of both com

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast